blue cross blue shield and glp 1 Alternatives to GLP-1 medication? Blue Cross Blue Shield plans

The newest kid on the block The ATTAIN-2 trial was conducted across 10 countries and involved more than 1,600 people who were obese or overweight with type 2 diabetes

A denial often comes down to the indication and your plans rules

Those with a history of thyroid cancer or pancreatitis may not want to take GLP-1 medications

Key terms include: $150 million upfront payment to Yao Pharma Up to $1.935 billion in development, regulatory, and commercial milestone payments Tiered royalties on future global sales Coverage across all therapeutic, diagnostic, and prophylactic indications for both human and veterinary use This structure positions the agreement as one of the larger oral-GLP-1 licensing deals in recent years